Mirum Pharmaceuticals (MIRM) Financials

$38.63 -0.96 (-2.42%)

Closing price 04/15/2025 04:00 PM Eastern

Extended Trading

$40.18 +1.55 (+4.01%)

As of 04/15/2025 04:22 PM Eastern

Annual Income Statements for Mirum Pharmaceuticals

This table shows Mirum Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-53	-103	-84	-136	-163	-88
Consolidated Net Income / (Loss)	-53	-103	-84	-136	-163	-88
Net Income / (Loss) Continuing Operations	-53	-103	-84	-135	-163	-88
Total Pre-Tax Income	-53	-103	-84	-142	-162	-87
Total Operating Income	-55	-104	-173	-131	-109	-88
Total Gross Profit	0.00	0.00	19	65	139	255
Total Revenue	0.00	0.00	19	77	186	337
Operating Revenue	-	0.00	19	77	186	337
Total Cost of Revenue	0.00	0.00	0.00	12	47	82
Operating Cost of Revenue	-	-	-	12	47	82
Total Operating Expenses	55	104	193	196	248	343
Selling, General & Admin Expense	12	23	59	89	146	202
Research & Development Expense	43	82	131	107	103	141
Total Other Income / (Expense), net	2.21	1.03	89	-11	-53	0.69
Interest Expense	0.00	0.34	18	16	64	14
Interest & Investment Income	2.23	1.56	0.37	3.86	14	14
Other Income / (Expense), net	-0.02	-0.19	107	0.91	-2.82	1.21
Income Tax Expense	0.02	0.01	0.04	-6.41	0.99	1.03
Basic Earnings per Share	($4.58)	($4.09)	($2.77)	($4.01)	($4.00)	($1.85)
Weighted Average Basic Shares Outstanding	11.49M	25.25M	30.32M	33.84M	40.89M	47.52M
Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	($4.02)	($4.00)	($1.85)
Weighted Average Diluted Shares Outstanding	11.49M	25.25M	30.32M	33.98M	40.89M	47.52M
Weighted Average Basic & Diluted Shares Outstanding	11.49M	25.25M	30.32M	37.95M	47.00M	49.01M

This table shows Mirum Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-36	-36	-30	-74	-24	-36	-25	-25	-14	-24
Consolidated Net Income / (Loss)	-36	-36	-30	-74	-24	-36	-25	-25	-14	-24
Net Income / (Loss) Continuing Operations	-36	-36	-30	-74	-24	-36	-25	-25	-14	-24
Total Pre-Tax Income	-36	-36	-30	-74	-23	-35	-25	-24	-14	-24
Total Operating Income	-33	-34	-27	-24	-25	-33	-26	-24	-13	-24
Total Gross Profit	19	16	27	31	37	45	51	58	70	77
Total Revenue	19	28	32	37	48	70	69	78	90	99
Operating Revenue	19	28	32	37	48	70	69	78	90	99
Total Cost of Revenue	0.00	12	4.98	6.81	10	25	18	20	21	23
Operating Cost of Revenue	-	-	4.98	6.81	10	25	18	20	21	23
Total Operating Expenses	52	50	54	55	63	77	78	82	82	101
Selling, General & Admin Expense	23	26	30	33	37	46	46	49	51	57
Research & Development Expense	26	31	24	22	26	31	32	33	32	44
Total Other Income / (Expense), net	-2.81	-2.50	-2.78	-49	1.81	-2.85	1.81	0.23	-1.20	-0.14
Interest Expense	3.97	4.36	4.24	53	3.57	3.56	3.58	3.57	3.59	3.58
Interest & Investment Income	1.35	2.14	2.27	3.63	4.06	3.78	3.63	3.49	3.47	3.20
Other Income / (Expense), net	-0.19	-0.28	-0.81	-0.27	1.32	-3.06	1.76	0.31	-1.09	0.23
Income Tax Expense	0.01	0.14	0.20	0.32	0.25	0.23	0.62	0.64	0.35	-0.58
Basic Earnings per Share	($1.02)	($0.98)	($0.80)	($1.94)	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)
Weighted Average Basic Shares Outstanding	34.93M	33.84M	37.68M	38.11M	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M
Diluted Earnings per Share	($1.02)	($0.99)	($0.80)	($1.94)	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)
Weighted Average Diluted Shares Outstanding	34.93M	33.98M	37.68M	38.11M	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M
Weighted Average Basic & Diluted Shares Outstanding	36.87M	37.95M	38.03M	38.30M	46.61M	47.00M	47.13M	47.71M	48.00M	49.01M

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-40	130	-11	-3.34	158	-63
Net Cash From Operating Activities	-39	-89	-133	-120	-71	10
Net Cash From Continuing Operating Activities	-39	-87	-133	-120	-71	10
Net Income / (Loss) Continuing Operations	-53	-103	-84	-136	-163	-88
Consolidated Net Income / (Loss)	-53	-103	-84	-136	-163	-88
Depreciation Expense	0.14	0.31	0.60	3.24	11	24
Amortization Expense	-0.14	0.25	-0.14	0.00	1.12	1.66
Non-Cash Adjustments To Reconcile Net Income	5.99	13	-66	40	100	50
Changes in Operating Assets and Liabilities, net	7.21	2.43	17	-28	-19	23
Net Cash From Investing Activities	-128	38	49	7.70	-107	-90
Net Cash From Continuing Investing Activities	-128	38	49	7.70	-107	-90
Purchase of Property, Plant & Equipment	-0.28	-0.23	-0.02	-0.28	-0.11	-0.99
Acquisitions	-	-	-19	0.00	-233	-20
Purchase of Investments	-152	-75	-198	-132	-27	-89
Sale and/or Maturity of Investments	25	113	158	140	153	20
Net Cash From Financing Activities	127	181	73	109	337	18
Net Cash From Continuing Financing Activities	127	181	73	109	337	18
Repurchase of Common Equity	0.00	-	0.00	0.00	-0.28	0.00
Issuance of Debt	-	-	0.00	0.00	305	0.00
Issuance of Common Equity	67	132	9.01	115	227	18
Other Financing Activities, net	0.00	50	64	-5.55	-196	0.00
Effect of Exchange Rate Changes	-	0.03	-0.00	0.01	-0.13	-1.30
Cash Interest Paid	-	-	0.00	0.00	6.82	13
Cash Income Taxes Paid	0.02	0.01	0.00	0.00	0.13	1.00

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-20	-7.76	21	148	5.83	-17	17	-69	-10	-0.47
Net Cash From Operating Activities	-26	-34	-19	-17	-18	-17	15	-3.80	3.98	-5.07
Net Cash From Continuing Operating Activities	-26	-34	-19	-17	-18	-17	15	-3.80	3.98	-5.07
Net Income / (Loss) Continuing Operations	-36	-36	-30	-74	-24	-36	-25	-25	-14	-24
Consolidated Net Income / (Loss)	-36	-36	-30	-74	-24	-36	-25	-25	-14	-24
Depreciation Expense	1.10	1.20	1.34	1.34	2.66	5.49	5.66	5.85	6.06	6.06
Amortization Expense	-0.58	0.69	0.00	0.31	0.41	0.40	0.41	0.41	0.42	0.42
Non-Cash Adjustments To Reconcile Net Income	11	9.23	13	59	7.94	21	13	15	8.41	14
Changes in Operating Assets and Liabilities, net	-1.82	-8.96	-2.63	-3.50	-5.64	-7.45	22	-0.79	3.33	-1.68
Net Cash From Investing Activities	-80	27	27	51	-183	-2.00	-0.01	-73	-18	0.64
Net Cash From Continuing Investing Activities	-80	27	27	51	-183	-2.00	-0.01	-73	-18	0.64
Purchase of Property, Plant & Equipment	-0.02	-0.24	-0.04	-0.07	-	-	-0.01	-0.78	-0.18	-0.02
Purchase of Investments	-118	-	-22	-4.89	-	-	0.00	-62	-16	-11
Sale and/or Maturity of Investments	38	27	65	56	30	3.00	0.00	-	7.75	12
Net Cash From Financing Activities	86	-0.33	13	115	207	1.78	1.21	7.29	3.86	5.34
Net Cash From Continuing Financing Activities	86	-0.33	13	115	207	1.78	1.21	7.29	3.86	5.34
Issuance of Common Equity	88	1.70	16	2.10	207	2.06	1.21	7.29	3.86	5.34
Effect of Exchange Rate Changes	-0.02	0.09	0.19	-0.11	-0.32	0.11	0.11	-0.12	0.09	-1.38
Cash Interest Paid	-	-	-	-	-	6.82	-	-	-	6.33
Cash Income Taxes Paid	-	-	0.00	-	-	0.13	0.14	0.20	0.43	0.23

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Total Assets	52	147	241	295	353	647	671
Total Current Assets	52	119	236	167	190	388	393
Cash & Equivalents	52	12	142	31	28	286	223
Restricted Cash	-	-	-	-	-	0.00	0.43
Short-Term Investments	0.00	105	90	125	124	0.00	58
Accounts Receivable	-	-	0.00	3.27	24	68	78
Inventories, net	-	-	0.00	1.51	5.57	22	22
Prepaid Expenses	0.01	2.70	4.53	5.27	8.95	11	12
Plant, Property, & Equipment, net	0.00	1.37	1.29	0.98	0.91	0.71	1.14
Total Noncurrent Assets	0.00	26	3.22	127	162	258	276
Long-Term Investments	0.00	23	0.00	4.98	-	0.00	13
Intangible Assets	-	-	0.00	19	59	253	250
Other Noncurrent Operating Assets	0.00	2.69	3.22	103	103	5.45	14
Total Liabilities & Shareholders' Equity	52	147	241	295	353	647	671
Total Liabilities	2.45	16	69	174	211	398	445
Total Current Liabilities	2.45	13	18	43	65	87	127
Accounts Payable	0.27	3.35	3.15	9.17	8.69	7.42	15
Accrued Expenses	2.18	9.33	13	31	54	79	110
Other Current Liabilities	0.00	0.40	1.90	2.71	2.02	1.10	1.71
Total Noncurrent Liabilities	0.00	3.29	50	132	146	311	319
Long-Term Debt	-	-	-	-	0.00	306	308
Other Noncurrent Operating Liabilities	0.00	3.29	50	132	146	4.47	10
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-17	130	172	120	142	249	226
Total Preferred & Common Equity	-17	130	172	120	142	249	226
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-17	130	172	120	142	249	226
Common Stock	0.04	200	345	377	535	803	870
Retained Earnings	-17	-70	-173	-257	-393	-556	-644
Accumulated Other Comprehensive Income / (Loss)	0.00	0.13	0.08	-0.04	-0.22	1.64	-0.37

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	364	334	444	651	652	661	668
Total Current Assets	216	172	384	389	389	368	387
Cash & Equivalents	36	49	297	303	303	233	223
Restricted Cash	-	-	-	0.00	-	0.25	0.43
Short-Term Investments	150	83	33	2.97	-	45	61
Accounts Receivable	16	25	35	48	55	60	69
Inventories, net	6.94	6.61	8.51	22	22	20	22
Prepaid Expenses	6.93	8.99	9.73	12	10	8.59	12
Plant, Property, & Equipment, net	0.80	0.88	0.87	0.79	0.50	1.10	1.21
Total Noncurrent Assets	148	160	59	261	262	292	280
Long-Term Investments	0.00	-	-	-	-	17	9.32
Intangible Assets	45	58	56	258	257	262	256
Other Noncurrent Operating Assets	103	103	2.77	2.94	4.55	13	15
Total Liabilities & Shareholders' Equity	364	334	444	651	652	661	668
Total Liabilities	195	192	365	382	417	432	436
Total Current Liabilities	51	49	58	75	106	112	116
Accounts Payable	11	6.44	14	7.37	16	9.84	9.55
Accrued Expenses	38	40	43	66	90	101	105
Other Current Liabilities	2.54	2.00	1.06	1.08	0.36	1.07	1.51
Total Noncurrent Liabilities	144	144	307	307	311	319	320
Long-Term Debt	-	-	306	306	307	307	308
Other Noncurrent Operating Liabilities	144	144	1.16	0.88	4.62	12	12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	169	141	79	269	235	229	232
Total Preferred & Common Equity	169	141	79	269	235	229	232
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	169	141	79	269	235	229	232
Common Stock	526	564	576	791	816	836	851
Retained Earnings	-356	-423	-497	-521	-582	-606	-620
Accumulated Other Comprehensive Income / (Loss)	-0.41	0.14	0.08	-1.46	-0.01	-0.48	0.92

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	302.66%	141.85%	80.76%
EBITDA Growth	0.00%	-89.78%	36.24%	-91.76%	21.28%	38.92%
EBIT Growth	0.00%	-90.80%	36.14%	-95.29%	14.07%	22.85%
NOPAT Growth	0.00%	-90.52%	-66.27%	24.33%	16.82%	19.74%
Net Income Growth	0.00%	-96.51%	18.67%	-61.53%	-20.45%	46.18%
EPS Growth	0.00%	10.70%	32.27%	-45.13%	0.50%	53.75%
Operating Cash Flow Growth	0.00%	-126.30%	-49.04%	9.51%	40.95%	114.55%
Free Cash Flow Firm Growth	0.00%	0.00%	-510.88%	11.67%	-187.37%	90.70%
Invested Capital Growth	0.00%	-521.94%	30.83%	76.56%	2,875.92%	-10.53%
Revenue Q/Q Growth	0.00%	0.00%	19.61%	47.36%	28.78%	9.73%
EBITDA Q/Q Growth	0.00%	-21.35%	59.72%	-282.02%	3.97%	18.60%
EBIT Q/Q Growth	0.00%	-21.31%	59.56%	-276.47%	-1.42%	11.89%
NOPAT Q/Q Growth	0.00%	-21.27%	-5.23%	8.00%	1.42%	8.71%
Net Income Q/Q Growth	0.00%	-22.91%	53.01%	-225.43%	0.47%	11.89%
EPS Q/Q Growth	0.00%	-417.05%	54.74%	-258.93%	6.98%	9.76%
Operating Cash Flow Q/Q Growth	0.00%	-33.96%	2.30%	-0.94%	19.92%	942.86%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-806.47%	46.87%	2.15%	24.28%
Invested Capital Q/Q Growth	0.00%	-342.60%	72.21%	39.68%	-0.11%	-2.05%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	83.94%	74.76%	75.77%
EBITDA Margin	0.00%	0.00%	-346.27%	-164.90%	-53.67%	-18.14%
Operating Margin	0.00%	0.00%	-906.12%	-170.28%	-58.57%	-26.00%
EBIT Margin	0.00%	0.00%	-348.66%	-169.10%	-60.08%	-25.64%
Profit (Net Income) Margin	0.00%	0.00%	-438.85%	-176.05%	-87.68%	-26.10%
Tax Burden Percent	100.04%	100.01%	100.04%	95.49%	100.61%	101.19%
Interest Burden Percent	95.92%	98.83%	125.81%	109.02%	145.05%	100.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-58.98%	-24.09%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	73.22%	-176.58%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	-24.67%	-13.00%
Return on Equity (ROE)	-58.43%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-132.03%	-12.97%
Operating Return on Assets (OROA)	0.00%	0.00%	-24.92%	-40.25%	-22.41%	-13.12%
Return on Assets (ROA)	0.00%	0.00%	-31.37%	-41.90%	-32.70%	-13.35%
Return on Common Equity (ROCE)	-36.72%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%
Return on Equity Simple (ROE_SIMPLE)	-40.32%	-60.01%	-69.87%	-95.51%	-65.72%	-38.97%
Net Operating Profit after Tax (NOPAT)	-38	-73	-121	-92	-76	-61
NOPAT Margin	0.00%	0.00%	-634.28%	-119.19%	-41.00%	-18.20%
Net Nonoperating Expense Percent (NNEP)	-10.17%	-16.28%	19.02%	-27.97%	-132.21%	152.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-64.67%	-13.76%	-11.49%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	16.06%	25.24%	24.23%
SG&A Expenses to Revenue	0.00%	0.00%	309.44%	115.58%	78.27%	60.03%
R&D to Revenue	0.00%	0.00%	686.74%	138.64%	55.06%	41.74%
Operating Expenses to Revenue	0.00%	0.00%	1,006.12%	254.22%	133.33%	101.77%
Earnings before Interest and Taxes (EBIT)	-55	-104	-67	-130	-112	-86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-104	-66	-127	-100	-61
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	4.32	2.61	4.07	5.06	5.53	8.80
Price to Tangible Book Value (P/TBV)	4.32	2.61	4.82	8.65	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	25.53	9.33	7.38	5.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	5.19	8.32
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	17.09	7.36	7.49	5.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	193.69
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	1.23	1.37
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	1.23	1.37
Financial Leverage	-1.07	-1.23	-1.35	-1.19	-0.34	0.07
Leverage Ratio	1.10	1.28	1.83	2.47	2.56	2.78
Compound Leverage Factor	1.06	1.27	2.30	2.69	3.71	2.79
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	55.20%	57.72%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	55.20%	57.72%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	44.80%	42.28%
Debt to EBITDA	0.00	0.00	0.00	0.00	-3.06	-5.04
Net Debt to EBITDA	0.00	0.00	0.00	0.00	-0.20	-0.24
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-3.06	-5.04
Debt to NOPAT	0.00	0.00	0.00	0.00	-4.01	-5.02
Net Debt to NOPAT	0.00	0.00	0.00	0.00	-0.26	-0.24
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-4.01	-5.02
Altman Z-Score	19.64	2.57	0.28	-0.09	1.14	1.88
Noncontrolling Interest Sharing Ratio	37.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	9.13	12.80	3.91	2.94	4.45	3.10
Quick Ratio	8.92	12.56	3.75	2.71	4.07	2.83
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-23	-140	-123	-355	-33
Operating Cash Flow to CapEx	-14,007.83%	-39,588.89%	-553,158.33%	-43,214.39%	-65,086.24%	1,039.78%
Free Cash Flow to Firm to Interest Expense	0.00	-68.31	-7.95	-7.73	-5.53	-2.31
Operating Cash Flow to Interest Expense	0.00	-265.90	-7.55	-7.52	-1.11	0.72
Operating Cash Flow Less CapEx to Interest Expense	0.00	-266.57	-7.55	-7.54	-1.11	0.65
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.07	0.24	0.37	0.51
Accounts Receivable Turnover	0.00	0.00	0.00	5.65	4.05	4.61
Inventory Turnover	0.00	0.00	0.00	3.50	3.37	3.65
Fixed Asset Turnover	0.00	0.00	16.83	81.33	230.09	365.19
Accounts Payable Turnover	0.00	0.00	0.00	1.39	5.84	7.41
Days Sales Outstanding (DSO)	0.00	0.00	0.00	64.56	90.05	79.23
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	104.39	108.16	99.95
Days Payable Outstanding (DPO)	0.00	0.00	0.00	263.35	62.49	49.25
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-94.40	135.72	129.93
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-9.60	-60	-41	-9.68	269	240
Invested Capital Turnover	0.00	0.00	-0.38	-3.02	1.44	1.32
Increase / (Decrease) in Invested Capital	0.00	-50	18	32	278	-28
Enterprise Value (EV)	424	217	327	567	1,396	2,000
Market Capitalization	564	449	489	719	1,376	1,985
Book Value per Share	$5.67	$6.69	$3.92	$3.85	$5.33	$4.70
Tangible Book Value per Share	$5.67	$6.69	$3.31	$2.25	($0.09)	($0.50)
Total Capital	130	172	120	142	555	534
Total Debt	0.00	0.00	0.00	0.00	306	308
Total Long-Term Debt	0.00	0.00	0.00	0.00	306	308
Net Debt	-140	-232	-162	-152	20	15
Capital Expenditures (CapEx)	0.28	0.23	0.02	0.28	0.11	0.99
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-10	-14	-33	-26	14	-15
Debt-free Net Working Capital (DFNWC)	106	218	124	125	300	266
Net Working Capital (NWC)	106	218	124	125	300	266
Net Nonoperating Expense (NNE)	14	30	-37	44	87	27
Net Nonoperating Obligations (NNO)	-140	-232	-162	-152	20	15
Total Depreciation and Amortization (D&A)	-0.00	0.55	0.46	3.24	12	25
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-170.05%	-34.03%	7.59%	-4.31%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	647.90%	162.85%	161.22%	79.03%
Net Working Capital to Revenue	0.00%	0.00%	647.90%	162.85%	161.22%	79.03%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.58)	($4.09)	($2.77)	($4.01)	($4.00)	($1.85)
Adjusted Weighted Average Basic Shares Outstanding	25.39M	30.42M	31.73M	33.84M	40.89M	47.52M
Adjusted Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	($4.02)	($4.00)	($1.85)
Adjusted Weighted Average Diluted Shares Outstanding	25.39M	30.42M	31.73M	33.98M	40.89M	47.52M
Adjusted Basic & Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.49M	25.25M	30.32M	37.95M	47.00M	49.01M
Normalized Net Operating Profit after Tax (NOPAT)	-38	-73	-121	-92	-76	-61
Normalized NOPAT Margin	0.00%	0.00%	-634.28%	-119.19%	-41.00%	-18.20%
Pre Tax Income Margin	0.00%	0.00%	-438.66%	-184.36%	-87.15%	-25.80%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-311.90	-3.79	-8.16	-1.74	-6.04
NOPAT to Interest Expense	0.00	-217.93	-6.90	-5.75	-1.19	-4.29
EBIT Less CapEx to Interest Expense	0.00	-312.58	-3.79	-8.17	-1.75	-6.11
NOPAT Less CapEx to Interest Expense	0.00	-218.60	-6.90	-5.77	-1.19	-4.35
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.17%	0.00%

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	275.60%	789.29%	145.10%	114.46%	154.13%	149.24%	119.07%	107.68%	89.37%	42.93%
EBITDA Growth	21.32%	-153.14%	18.07%	22.28%	36.26%	8.60%	30.01%	22.90%	64.86%	41.12%
EBIT Growth	20.31%	-156.22%	14.99%	17.93%	27.96%	-3.50%	11.62%	2.55%	42.20%	32.70%
NOPAT Growth	23.22%	47.52%	17.07%	22.80%	23.52%	4.61%	2.50%	0.17%	49.56%	25.67%
Net Income Growth	24.20%	-163.31%	17.69%	-175.01%	33.94%	2.12%	16.10%	66.72%	39.65%	33.28%
EPS Growth	34.19%	-151.83%	31.62%	-130.95%	44.12%	30.30%	32.50%	73.20%	47.37%	28.99%
Operating Cash Flow Growth	23.91%	-3.39%	52.67%	14.08%	29.99%	51.51%	181.03%	78.06%	121.86%	69.50%
Free Cash Flow Firm Growth	-247.96%	13.19%	17.02%	43.30%	-94.55%	-442.39%	-320.01%	-137.63%	104.85%	103.77%
Invested Capital Growth	89.20%	76.56%	129.30%	480.39%	1,776.47%	2,875.92%	2,528.57%	343.24%	-8.76%	-10.53%
Revenue Q/Q Growth	7.41%	48.59%	13.23%	18.67%	27.28%	45.74%	-0.48%	12.50%	16.05%	10.00%
EBITDA Q/Q Growth	-10.49%	0.02%	21.45%	13.97%	9.39%	-43.37%	37.44%	5.23%	58.71%	-140.25%
EBIT Q/Q Growth	-10.58%	-4.13%	17.95%	12.20%	2.94%	-49.61%	30.68%	3.20%	42.43%	-74.21%
NOPAT Q/Q Growth	-4.58%	-3.89%	20.53%	10.59%	-3.60%	-29.57%	18.77%	8.45%	47.66%	-90.97%
Net Income Q/Q Growth	-32.63%	-2.03%	17.30%	-145.73%	68.14%	-51.17%	29.11%	2.54%	42.22%	-67.12%
EPS Q/Q Growth	-21.43%	2.94%	19.19%	-142.50%	70.62%	-21.05%	21.74%	3.70%	42.31%	-63.33%
Operating Cash Flow Q/Q Growth	-29.02%	-31.68%	45.22%	7.69%	-5.14%	8.80%	191.54%	-125.00%	204.76%	-227.21%
Free Cash Flow Firm Q/Q Growth	-3.15%	64.30%	-6.33%	-44.82%	-253.97%	0.49%	17.66%	18.07%	107.23%	-22.74%
Invested Capital Q/Q Growth	-12.51%	39.68%	193.75%	497.85%	395.83%	-0.11%	-11.23%	0.81%	2.06%	-2.05%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	55.66%	84.24%	81.83%	78.57%	64.03%	74.24%	74.03%	76.98%	77.09%
EBITDA Margin	-173.38%	-116.65%	-84.25%	-61.08%	-43.48%	-42.78%	-26.92%	-22.68%	-8.07%	-17.62%
Operating Margin	-175.09%	-122.41%	-85.92%	-64.73%	-52.69%	-46.85%	-38.24%	-31.12%	-14.03%	-24.36%
EBIT Margin	-176.11%	-123.41%	-88.48%	-65.46%	-49.92%	-51.25%	-35.70%	-30.72%	-15.24%	-24.13%
Profit (Net Income) Margin	-190.13%	-130.55%	-95.35%	-197.45%	-49.42%	-51.27%	-36.52%	-31.64%	-15.75%	-23.93%
Tax Burden Percent	100.04%	100.39%	100.67%	100.43%	101.07%	100.64%	102.53%	102.65%	102.50%	97.64%
Interest Burden Percent	107.92%	105.37%	107.05%	300.33%	97.96%	99.41%	99.77%	100.35%	100.85%	101.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-262.31%	-42.20%	-47.18%	-48.41%	-39.07%	-11.72%	-22.57%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-185.89%	-35.74%	-27.66%	-37.87%	80.89%	-91.27%	-61.72%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	146.61%	15.11%	9.32%	12.91%	-3.37%	-2.45%	-4.54%
Return on Equity (ROE)	-36.94%	-103.46%	-103.32%	-115.70%	-27.09%	-37.86%	-35.51%	-42.43%	-14.18%	-27.11%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,410.11%	-279.10%	-134.77%	-132.03%	-246.66%	-177.86%	-16.95%	-12.97%
Operating Return on Assets (OROA)	-30.72%	-29.37%	-27.71%	-20.46%	-14.24%	-19.11%	-16.23%	-14.71%	-7.10%	-12.34%
Return on Assets (ROA)	-33.17%	-31.07%	-29.86%	-61.72%	-14.09%	-19.12%	-16.60%	-15.15%	-7.34%	-12.24%
Return on Common Equity (ROCE)	-36.94%	-103.46%	-103.32%	-115.70%	-27.09%	-37.86%	-35.51%	-42.43%	-14.18%	-27.11%
Return on Equity Simple (ROE_SIMPLE)	-24.62%	0.00%	-91.53%	-224.28%	-61.02%	0.00%	-67.59%	-47.67%	-43.02%	0.00%
Net Operating Profit after Tax (NOPAT)	-23	-24	-19	-17	-18	-23	-19	-17	-8.88	-17
NOPAT Margin	-122.56%	-85.69%	-60.14%	-45.31%	-36.89%	-32.79%	-26.77%	-21.78%	-9.82%	-17.06%
Net Nonoperating Expense Percent (NNEP)	-6.50%	-7.99%	-8.18%	-76.42%	-6.46%	-19.52%	-10.54%	-119.96%	79.55%	39.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-16.84%	-	-	-	-4.11%	-	-	-	-3.18%
Cost of Revenue to Revenue	0.00%	44.34%	15.76%	18.17%	21.43%	35.97%	25.76%	25.97%	23.02%	22.91%
SG&A Expenses to Revenue	119.88%	94.85%	95.64%	87.87%	76.54%	66.40%	65.93%	63.19%	55.93%	57.17%
R&D to Revenue	139.60%	111.46%	74.52%	58.70%	54.72%	44.48%	46.55%	41.95%	35.09%	44.29%
Operating Expenses to Revenue	275.09%	178.07%	170.16%	146.57%	131.26%	110.88%	112.48%	105.14%	91.01%	101.45%
Earnings before Interest and Taxes (EBIT)	-33	-34	-28	-25	-24	-36	-25	-24	-14	-24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-33	-33	-27	-23	-21	-30	-19	-18	-7.29	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.06	5.06	6.46	12.52	4.50	5.53	5.03	7.04	8.02	8.80
Price to Tangible Book Value (P/TBV)	5.54	8.65	10.92	44.37	112.65	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	13.16	9.33	9.52	8.50	8.36	7.38	5.27	6.10	6.06	5.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	85.88	17.68	4.50	5.19	4.97	6.75	7.63	8.32
Enterprise Value to Revenue (EV/Rev)	9.61	7.36	8.14	8.29	8.36	7.49	5.29	6.14	6.10	5.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	193.69
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	3.89	1.14	1.23	1.31	1.34	1.33	1.37
Long-Term Debt to Equity	0.00	0.00	0.00	3.89	1.14	1.23	1.31	1.34	1.33	1.37
Financial Leverage	-1.73	-1.19	-1.09	-0.79	-0.42	-0.34	-0.34	-0.04	0.03	0.07
Leverage Ratio	2.66	2.47	2.45	3.91	2.32	2.56	2.62	3.59	2.63	2.78
Compound Leverage Factor	2.87	2.60	2.62	11.75	2.27	2.54	2.62	3.60	2.65	2.82
Debt to Total Capital	0.00%	0.00%	0.00%	79.54%	53.21%	55.20%	56.67%	57.30%	57.01%	57.72%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	79.54%	53.21%	55.20%	56.67%	57.30%	57.01%	57.72%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	20.46%	46.79%	44.80%	43.33%	42.70%	42.99%	42.28%
Debt to EBITDA	0.00	0.00	0.00	-2.64	-2.94	-3.06	-3.27	-3.47	-4.10	-5.04
Net Debt to EBITDA	0.00	0.00	0.00	0.21	0.00	-0.20	-0.04	-0.13	-0.18	-0.24
Long-Term Debt to EBITDA	0.00	0.00	0.00	-2.64	-2.94	-3.06	-3.27	-3.47	-4.10	-5.04
Debt to NOPAT	0.00	0.00	0.00	-3.69	-3.95	-4.01	-4.04	-4.05	-4.58	-5.02
Net Debt to NOPAT	0.00	0.00	0.00	0.29	0.00	-0.26	-0.05	-0.15	-0.20	-0.24
Long-Term Debt to NOPAT	0.00	0.00	0.00	-3.69	-3.95	-4.01	-4.04	-4.05	-4.58	-5.02
Altman Z-Score	1.13	0.81	1.52	1.01	1.46	1.53	1.19	1.70	2.14	2.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.19	2.94	3.53	6.59	5.20	4.45	3.68	3.28	3.34	3.10
Quick Ratio	3.92	2.71	3.21	6.28	4.74	4.07	3.38	3.02	3.05	2.83
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-156	-56	-59	-86	-303	-301	-248	-203	15	11
Operating Cash Flow to CapEx	-136,973.68%	-14,161.16%	-45,790.24%	-25,486.76%	0.00%	0.00%	117,015.38%	-488.19%	2,201.11%	-25,340.00%
Free Cash Flow to Firm to Interest Expense	-39.18	-12.74	-13.92	-1.62	-84.70	-84.55	-69.34	-56.94	4.10	3.17
Operating Cash Flow to Interest Expense	-6.55	-7.86	-4.43	-0.33	-5.10	-4.66	4.25	-1.07	1.11	-1.42
Operating Cash Flow Less CapEx to Interest Expense	-6.56	-7.92	-4.44	-0.33	-5.10	-4.66	4.25	-1.28	1.06	-1.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.17	0.24	0.31	0.31	0.29	0.37	0.45	0.48	0.47	0.51
Accounts Receivable Turnover	6.25	5.65	5.89	4.70	4.51	4.05	5.62	5.52	5.28	4.61
Inventory Turnover	0.00	3.50	1.22	1.81	1.51	3.37	0.91	1.81	1.68	3.65
Fixed Asset Turnover	56.38	81.33	107.91	136.37	182.97	230.09	325.11	268.81	307.18	365.19
Accounts Payable Turnover	0.00	1.39	0.87	1.05	2.46	5.84	1.15	2.16	4.36	7.41
Days Sales Outstanding (DSO)	58.41	64.56	62.00	77.73	80.92	90.05	64.90	66.10	69.17	79.23
Days Inventory Outstanding (DIO)	0.00	104.39	300.31	201.72	241.96	108.16	400.74	201.13	217.17	99.95
Days Payable Outstanding (DPO)	0.00	263.35	417.23	349.26	148.50	62.49	318.43	168.76	83.78	49.25
Cash Conversion Cycle (CCC)	58.41	-94.40	-54.93	-69.80	174.38	135.72	147.21	98.47	202.56	129.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-16	-9.68	9.08	54	269	269	239	241	245	240
Invested Capital Turnover	-0.64	-3.02	-8.75	5.79	1.14	1.44	1.81	1.79	1.19	1.32
Increase / (Decrease) in Invested Capital	133	32	40	69	285	278	230	186	-24	-28
Enterprise Value (EV)	503	567	780	960	1,210	1,396	1,185	1,623	1,874	2,000
Market Capitalization	688	719	912	984	1,210	1,376	1,181	1,611	1,861	1,985
Book Value per Share	$5.17	$3.85	$3.72	$2.07	$7.03	$5.33	$4.99	$4.86	$4.86	$4.70
Tangible Book Value per Share	$3.79	$2.25	$2.20	$0.58	$0.28	($0.09)	($0.49)	($0.70)	($0.50)	($0.50)
Total Capital	169	142	141	384	575	555	541	536	540	534
Total Debt	0.00	0.00	0.00	306	306	306	307	307	308	308
Total Long-Term Debt	0.00	0.00	0.00	306	306	306	307	307	308	308
Net Debt	-185	-152	-132	-24	-0.01	20	3.99	12	13	15
Capital Expenditures (CapEx)	0.02	0.24	0.04	0.07	0.00	0.00	0.01	0.78	0.18	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-26	-8.58	-4.64	7.89	14	-19	-23	-14	-15
Debt-free Net Working Capital (DFNWC)	164	125	123	325	314	300	284	256	271	266
Net Working Capital (NWC)	164	125	123	325	314	300	284	256	271	266
Net Nonoperating Expense (NNE)	13	13	11	57	5.98	13	6.75	7.68	5.36	6.83
Net Nonoperating Obligations (NNO)	-185	-152	-132	-24	-0.01	20	3.99	12	13	15
Total Depreciation and Amortization (D&A)	0.51	1.89	1.34	1.64	3.07	5.89	6.08	6.26	6.48	6.47
Debt-free, Cash-free Net Working Capital to Revenue	-40.52%	-34.03%	-8.96%	-4.01%	5.45%	7.59%	-8.61%	-8.74%	-4.56%	-4.31%
Debt-free Net Working Capital to Revenue	313.91%	162.85%	128.95%	280.97%	216.90%	161.22%	126.59%	96.65%	88.22%	79.03%
Net Working Capital to Revenue	313.91%	162.85%	128.95%	280.97%	216.90%	161.22%	126.59%	96.65%	88.22%	79.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.02)	($0.98)	($0.80)	($1.94)	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)
Adjusted Weighted Average Basic Shares Outstanding	34.93M	33.84M	37.68M	38.11M	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M
Adjusted Diluted Earnings per Share	($1.02)	($0.99)	($0.80)	($1.94)	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)
Adjusted Weighted Average Diluted Shares Outstanding	34.93M	33.98M	37.68M	38.11M	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.87M	37.95M	38.03M	38.30M	46.61M	47.00M	47.13M	47.71M	48.00M	49.01M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-24	-19	-17	-18	-23	-19	-17	-8.88	-17
Normalized NOPAT Margin	-122.56%	-85.69%	-60.14%	-45.31%	-36.89%	-32.79%	-26.77%	-21.78%	-9.82%	-17.06%
Pre Tax Income Margin	-190.06%	-130.05%	-94.72%	-196.61%	-48.90%	-50.94%	-35.62%	-30.82%	-15.37%	-24.51%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.33	-7.90	-6.59	-0.46	-6.67	-10.00	-6.91	-6.70	-3.84	-6.70
NOPAT to Interest Expense	-5.80	-5.49	-4.48	-0.32	-4.93	-6.40	-5.18	-4.75	-2.48	-4.74
EBIT Less CapEx to Interest Expense	-8.33	-7.96	-6.60	-0.47	-6.67	-10.00	-6.91	-6.92	-3.89	-6.71
NOPAT Less CapEx to Interest Expense	-5.80	-5.54	-4.49	-0.32	-4.93	-6.40	-5.18	-4.97	-2.53	-4.74
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.17%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Mirum Pharmaceuticals' Financials

When does Mirum Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Mirum Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Mirum Pharmaceuticals' net income changed over the last 5 years?

Mirum Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$87.94 million in 2024, rising from -$52.55 million in 2019. The previous period was -$163.42 million in 2023.

What is Mirum Pharmaceuticals's operating income?

Mirum Pharmaceuticals's total operating income in 2024 was -$87.61 million, based on the following breakdown:

Total Gross Profit: $255.25 million
Total Operating Expenses: $342.85 million

How has Mirum Pharmaceuticals revenue changed over the last 5 years?

Over the last 5 years, Mirum Pharmaceuticals' total revenue changed from $0.00 in 2019 to $336.89 million in 2024, a change of 33,688,800,000.0%.

How much debt does Mirum Pharmaceuticals have?

Mirum Pharmaceuticals' total liabilities were at $445.11 million at the end of 2024, a 11.9% increase from 2023, and a 18,075.3% increase since 2018.

How much cash does Mirum Pharmaceuticals have?

In the past 6 years, Mirum Pharmaceuticals' cash and equivalents has ranged from $11.97 million in 2019 to $286.33 million in 2023, and is currently $222.50 million as of their latest financial filing in 2024.

How has Mirum Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Mirum Pharmaceuticals' book value per share changed from 5.67 in 2019 to 4.70 in 2024, a change of -17.1%.

Remove Ads

Related Companies

This page (NASDAQ:MIRM) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Financials

Frequently Asked Questions About Mirum Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Financials

Annual Income Statements for Mirum Pharmaceuticals

Quarterly Income Statements for Mirum Pharmaceuticals

Annual Cash Flow Statements for Mirum Pharmaceuticals

Quarterly Cash Flow Statements for Mirum Pharmaceuticals

Annual Balance Sheets for Mirum Pharmaceuticals

Quarterly Balance Sheets for Mirum Pharmaceuticals

Annual Metrics and Ratios for Mirum Pharmaceuticals

Quarterly Metrics and Ratios for Mirum Pharmaceuticals

Frequently Asked Questions About Mirum Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools